These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17852160)

  • 41. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
    Junquera L; Gallego L
    J Oral Maxillofac Surg; 2008 Jul; 66(7):1516-7. PubMed ID: 18571043
    [No Abstract]   [Full Text] [Related]  

  • 42. Animal models of osteonecrosis of the jaw.
    Allen MR
    J Musculoskelet Neuronal Interact; 2007; 7(4):358-60. PubMed ID: 18094512
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.
    Etminan M; Aminzadeh K; Matthew IR; Brophy JM
    J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.
    Bertoldo F; Santini D; Lo Cascio V
    Nat Clin Pract Oncol; 2007 Dec; 4(12):711-21. PubMed ID: 18037875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonate related osteonecrosis of the jaws.
    Fung E
    J Rheumatol; 2009 Feb; 36(2):450; author reply 453. PubMed ID: 19208578
    [No Abstract]   [Full Text] [Related]  

  • 47. Safety profile of intravenous bisphosphonates.
    Mehrotra B
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER; Basile JD
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonates, osteonecrosis of the jaw, and dental treatment recommendations.
    Radfar L; Masood F
    J Okla Dent Assoc; 2008; 99(7):28-9. PubMed ID: 18595621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteonecrosis of jaws after bisphosphonates: an internet resource on the web for dentist.
    Hon NC
    Singapore Dent J; 2007 Dec; 29(1):19-21. PubMed ID: 18472526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw.
    Chu V; ;
    Hawaii Dent J; 2008; 39(5):9-12; quiz 17. PubMed ID: 19189512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates.
    Nastro E; Allegra A; Oteri G; Ferlito S; Alonci A; Bellomo G; D'Angelo A; Tolomeo A; Cicciù D; De Ponte FS; Musolino C
    J Oral Maxillofac Surg; 2009 Dec; 67(12):2701-3. PubMed ID: 19926001
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical guidelines for prevention of osteonecrosis of the jaws in patients in treatment with bisphosphonates: literature review and report of three cases.
    Sarzi Amadè D; Tallarico M; Loreti MC; Montecchi PP; Niccoli A
    Minerva Stomatol; 2008 Sep; 57(9):429-46. PubMed ID: 18923378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bisphosphonate-associated osteonecrosis can hide jaw metastases.
    Bedogni A; Saia G; Ragazzo M; Bettini G; Capelli P; D'Alessandro E; Nocini PF; Lo Russo L; Lo Muzio L; Blandamura S
    Bone; 2007 Dec; 41(6):942-5. PubMed ID: 17905677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
    Tubiana-Hulin M; Spielmann M; Roux C; Campone M; Zelek L; Gligorov J; Samson J; Lesclous P; Laredo JD; Namer M
    Crit Rev Oncol Hematol; 2009 Jul; 71(1):12-21. PubMed ID: 19070505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
    Jeffcoat M; Watts NB
    Gen Dent; 2008; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 59. Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment.
    Pérez SB; Barrero MV; Hernández MS; Knezevic M; Navarro JM; Millares JR
    Med Oral Patol Oral Cir Bucal; 2008 Dec; 13(12):E770-3. PubMed ID: 19047964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series.
    Saussez S; Javadian R; Hupin C; Magremanne M; Chantrain G; Loeb I; Decaestecker C
    Laryngoscope; 2009 Feb; 119(2):323-9. PubMed ID: 19172621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.